Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
September 23, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...
August 28, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
August 08, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
August 07, 2024 07:40 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
August 07, 2024 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase CAPLYTA’s strong prescription uptake continues: Q2...
July 24, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
June 18, 2024 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint...
June 10, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
May 29, 2024 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...